Search research articles
Contact Us
Filters
Showing results (101-110 of 133) with videos related to
Page
of 14
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
Xiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.
Nature Communications
|
May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
Hitoshi Dejima, Xin Hu, Runzhe Chen, et al.
Research Square
|
May 27, 2024
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion
Xin Hu, Bo Zhu, Natalie Vokes, et al.
Cancer Discovery
|
February 22, 2019
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Grant M Fischer, Ali Jalali, David A Kircher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2020
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC
Pierre-Olivier Gaudreau, Marcelo V Negrao, Kyle G Mitchell, et al.
Journal for Immunotherapy of Cancer
|
August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Marcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications
|
April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
Akash Mitra, Miles C Andrews, Whijae Roh, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Communications
|
May 13, 2021
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
Xin Hu, Junya Fujimoto, Lisha Ying, et al.
Cell
|
November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 133) with videos related to
Sort By:
Page
of 14
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target
Xiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.
Nature Communications
|
May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
Hitoshi Dejima, Xin Hu, Runzhe Chen, et al.
Research Square
|
May 27, 2024
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion
Xin Hu, Bo Zhu, Natalie Vokes, et al.
Cancer Discovery
|
February 22, 2019
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases
Grant M Fischer, Ali Jalali, David A Kircher, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2020
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC
Pierre-Olivier Gaudreau, Marcelo V Negrao, Kyle G Mitchell, et al.
Journal for Immunotherapy of Cancer
|
August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Marcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications
|
April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
Akash Mitra, Miles C Andrews, Whijae Roh, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Communications
|
May 13, 2021
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
Xin Hu, Junya Fujimoto, Lisha Ying, et al.
Cell
|
November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Moshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.
Page
of 14